scholarly journals Outcomes for Patients With Intermediate-, High-, and Very-High-Risk Prostate Cancer Treated With a Combination of External Beam Radiation Therapy and Brachytherapy

2015 ◽  
Vol 93 (3) ◽  
pp. E199-E200
Author(s):  
J. Kiffel ◽  
E.R. Kiffel ◽  
A.L. Mandel ◽  
N.N. Stone ◽  
R.G. Stock
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
High Risk ◽  
External Beam Radiation Therapy ◽  
External Beam Radiation ◽  
External Beam ◽  
Beam Radiation ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer ◽  
Very High

Do Not Count Out External-Beam Radiation Therapy for High-Risk Prostate Cancer

2010 ◽  
Vol 28 (28) ◽  
pp. e518-e519 ◽  
Author(s):  
Daniel A. Hamstra ◽  
Jeff M. Michalski ◽  
Mack Roach ◽  
Howard M. Sandler
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
High Risk ◽  
External Beam Radiation Therapy ◽  
External Beam Radiation ◽  
External Beam ◽  
Beam Radiation ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer

Comparison of Neoadjuvant vs Concurrent/Adjuvant Androgen Deprivation in Men with High-risk Prostate Cancer Receiving Definitive Radiation Therapy

2017 ◽  
Vol 103 (4) ◽  
pp. 387-393
Author(s):  
Anna Lee ◽  
Daniel J. Becker ◽  
Ariel J. Lederman ◽  
Virginia W. Osborn ◽  
Meng S. Shao ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Radiation Therapy ◽  
High Risk ◽  
External Beam Radiation Therapy ◽  
External Beam Radiation ◽  
External Beam ◽  
Beam Radiation ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer

Purpose It is unknown whether there is a benefit to starting androgen deprivation therapy (ADT) prior to rather than concurrently with definitive radiation therapy in men with high-risk prostate cancer. We studied the National Cancer Data Base to determine whether the timing of ADT impacts survival. Methods Men diagnosed with high-risk prostate adenocarcinoma who received external beam radiation therapy (EBRT) to a dose of 70-81 Gy along with ADT from 2004-2011 were included. Those who started ADT 42-90 days before EBRT were identified as having received neoadjuvant hormonal therapy (N-HT) and those who received ADT from 14 days before their radiation until 84 days after the start of EBRT were categorized as receiving concurrent/adjuvant treatment (C-HT). We used the log-rank test to compare Kaplan-Meier survival curves and multivariable Cox regression to assess the impact of covariables on overall survival (OS). Results Among 11,491 included patients, those receiving N-HT were 1 year older ( p<0.001) and more likely to have Gleason 8-10 disease ( p = 0.01) and cT3-4 disease ( p = 0.002). Men receiving N-HT had a 5-year and median OS of 80.6% and 111.4 months, respectively, compared to 78.3% and 108.9 months, respectively, in those receiving C-HT ( p = 0.03). This benefit remained significant on multivariable analysis (hazard ratio 0.86, 95% confidence interval 0.77-0.96, p = 0.008). Duration of ADT was not available to report. Conclusions External beam radiation therapy with N-HT was associated with improved overall survival compared to C-HT. This study is hypothesis-generating and further studies are needed to best qualify the sequencing of hormone therapy with the duration of treatment.

Sign in / Sign up

Export Citation Format

Share Document